Suppr超能文献

拉莫三嗪对双相情感障碍合并酒精依赖患者的影响。

Effects of lamotrigine in patients with bipolar disorder and alcohol dependence.

作者信息

Rubio Gabriel, López-Muñoz Francisco, Alamo Cecilio

机构信息

Retiro Health Mental Services, Madrid, Spain.

出版信息

Bipolar Disord. 2006 Jun;8(3):289-93. doi: 10.1111/j.1399-5618.2006.00292.x.

Abstract

BACKGROUND

Bipolar disorder is significantly associated with alcohol use disorders. Anticonvulsant drugs are used in the treatment of bipolar disorder and they have also been used to treat alcohol dependence. The purpose of the present study was to evaluate tolerance and safety of lamotrigine in a dual-diagnosis population presenting bipolar disorder and alcohol dependence. Open-label lamotrigine was examined in 28 outpatients with DSM-IV bipolar disorder and alcohol dependence. Lamotrigine was added to existing medication regimens.

METHOD

Lamotrigine was started at a dose of 25 mg/day and titrated to a maximum dose of 300 mg/day. Subjects received a baseline evaluation which included a Structured Clinical Interview for DSM-IV (SCID) and weekly assessments for 12 weeks with the Hamilton Rating Scale for Depression (HAM-D), Young Mania Rating Scale (YMRS), Brief Psychiatric Rating Scale (BPRS), Severity of Alcohol Dependence Scale (SADS), a Visual Analogue Scale for Craving severity (VASC), and alcohol consumption. The concentration of carbohydrate-deficient transferrin (CDT) was used as an indirect measure of alcohol consumption. The sample consisted of 18 men and 10 women diagnosed with alcohol dependence and bipolar disorder I (n = 21) or bipolar disorder II (n = 7), with a mean age of 36.5 +/- 7.7 years.

RESULTS

Significant improvement was observed in HAM-D, YMRS, and BPRS scores (p < 0.01). Craving and CDT also significantly decreased (p < 0.001). Lamotrigine was well tolerated with no dropout subjects due to adverse events.

CONCLUSION

Lamotrigine is safe and well tolerated in this sample and associated with improvement in mood, alcohol craving and alcohol consumption. A placebo-controlled study would be of interest.

摘要

背景

双相情感障碍与酒精使用障碍显著相关。抗惊厥药物用于双相情感障碍的治疗,也被用于治疗酒精依赖。本研究的目的是评估拉莫三嗪在双相情感障碍和酒精依赖双重诊断人群中的耐受性和安全性。对28例符合DSM-IV双相情感障碍和酒精依赖的门诊患者进行了开放标签的拉莫三嗪研究。拉莫三嗪被添加到现有的药物治疗方案中。

方法

拉莫三嗪起始剂量为25mg/天,滴定至最大剂量300mg/天。受试者接受基线评估,包括DSM-IV结构化临床访谈(SCID),并在12周内每周使用汉密尔顿抑郁量表(HAM-D)、杨氏躁狂量表(YMRS)、简明精神病评定量表(BPRS)、酒精依赖严重程度量表(SADS)、渴求严重程度视觉模拟量表(VASC)以及酒精摄入量进行评估。缺乏碳水化合物转铁蛋白(CDT)的浓度被用作酒精摄入量的间接测量指标。样本包括18名男性和10名女性,诊断为酒精依赖和I型双相情感障碍(n = 21)或II型双相情感障碍(n = 7),平均年龄为36.5±7.7岁。

结果

HAM-D、YMRS和BPRS评分有显著改善(p < 0.01)。渴求感和CDT也显著降低(p < 0.001)。拉莫三嗪耐受性良好,无受试者因不良事件退出研究。

结论

在本样本中,拉莫三嗪安全且耐受性良好,并与情绪改善、酒精渴求感及酒精摄入量降低相关。一项安慰剂对照研究将很有意义。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验